Accessibility options |

WLMHT 'top recruiter' for Alzheimer's study

18 Jul 2016

WLMHT’s clinical trials facility has gained recognition for being the top recruiter in the UK for an Alzheimer’s medication trial, which is investigating whether a drug can improve cognitive performance in people diagnosed with Alzheimer’s when it is taken alongside their current dementia medication.

Elderly woman outsideLocally the study is led by Professor Craig Ritchie and has involved dementia patients and their carers from all three boroughs covered by the trust.

Alzheimer’s is an irreversible, chronic and progressive neurodegenerative disease, which gradually leads to the deterioration of memory, as well as the ability to learn, reason, make judgments, communicate, and carry out daily activities.

Prem Mandalia, research assistant at the clinical trials facility in Isleworth, said: “I joined the team in February and have been extremely impressed with each and every one of my colleagues for all their hard work and effort. Every psychiatrist, nurse, therapist and psychologist who talked to their patients about the study (or about research in general) allowed so many people to get access to this opportunity.

“The team was especially effective in using the national recruitment database ‘Join Dementia Research’ to give people in the local area with Alzheimer’s disease, but who aren’t under the care of our trust, the opportunity to participate. We hope that our efforts can contribute to further understanding the efficacy of this drug to treat patients with Alzheimer’s.”

Clinical research is the only way that we can improve current treatments and discover new tests, treatments and medications. Research is a big priority for WLMHT and we are committed to providing more opportunities for patients to get involved in research studies.

To find out more about getting involved in research, speak to your clinical team or contact us at research@wlmht.nhs.uk.

The study is on-going, with participants completing study assessments until December 2016. The clinical trials facility expect the results of the study to be available in 2017.